Objective To investigate the efficacy and safety of ritodrine in treatment of late abortion.Methods 80 patients with the signs of late abortion were randomly divided into ritodrine group and magnesium sulfate group, with 40 in each group.The ritodrine group intravenously received 50 ml ritodrine added into 250 ml glucose solution( 5％ ).The initial dose was 5 drops/min, with an increase of 5 drops/min every 10 min, and maintained until uterine contractions were inhibited for 12 h.30 min before stopping infusion, the ritodrine group received a tablet of oral ritodrine (10 mg/tablet )every 2 h at the fist day, and was reduced to a tablet every 4 h at the second day, and a tablet every 6 h at the third day,maintained for 3 days.Magnesium sulfate group received 20 ml of magnesium sulfate added to 100 ml of 5％ glucose solution, and completely infused in an hour.Intravenous dripping was maintained at the speed of 1-2 g/h until uterine contractions werd inhibited for 12 h, and the total dose was no more than 25 g.Inhibition and disappearance time of uterine contractions, treatment failure and adverse drug reactions were compared.Results When compared with that in magnesium sulfate group, the inhibition and disappearance time of uterine contractions were shorter and the treatment failure rate was lower in ritodrine group, and the difference was statistically significant ( P ＜ 0.01, P ＜ 0.05 ), but the difference of adverse drug reactions between the two groups was not statistically significant ( P ＞ O.05).Conclusion Ritodrine is safe and effective in the treatment of late abortion.%目的 探讨利托君治疗晚期流产的效果及安全性.方法 选择有晚期流产征象的80例随机分为利托君组和硫酸镁组,每组各40例.利托君组予利托君50 ml加入5%葡萄糖注射液250 ml静脉滴注,起始剂量5滴/min,每隔10 min增加5滴/min,维持滴注到宫缩抑制后12 h.滴注停止前30 min改口服利托君片,第1天2 h 1片(10 mg/片),第2天4 h 1片,第3天6 h 1片,维持3 d后停药.硫酸镁组予25%硫酸镁注射液20 ml加入5%葡萄糖注射液100 ml,1 h内静脉滴注完毕,以后以1～2 g/h静脉滴注维持,每天总量不超过25 g,至宫缩抑制后12 h停药.比较两组抑制宫缩与宫缩消失时间、治疗失败率和药物不良反应.结果 利托君组宫缩抑制时间及宫缩消失时间均短于硫酸镁组,治疗失败率低于硫酸镁组,差异均有统计学意义(P0.05).结论 利托君治疗晚期流产抑制宫缩显效快,安全有效.
展开▼
